It is trading at $2.05 which is just a bit below $2.16, the stock’s 50 day moving average and a tad under the 200 day moving average of $2.19. The 50 day moving average was down $-0.11 or -5.14% and the 200 day average was down $-0.14. Trading was light with 2,766 shares changing hands on Tuesday. Trading volume was down 98.69% under the stocks average daily volume.
Investors are more bullish on Affimed N.V. recently if you put credence in the change in short interest. The company realized a fall in short interest from September 15, 2017 to September 29, 2017 of -42.55%. Short interest decreased from 712,056 to 409,062 over that period. With short interest at 409,062 and short average daily volume at 386,134, the short-interest ratio is 1.0 and the percentage of shorted shares was 0.01% on September 29.
These funds have shifted positions in (AFMD). As of the end of the quarter Perceptive Advisors LLC had disposed of 66,087 shares trimming its stake by 9.0%. The value of the investment in AFMD went from $1,689,000 to $1,369,000 a change of $320,000 for the reporting period. As of quarter end Orbimed Advisors LLC had sold a total of 219,200 shares trimming its position 10.9%. The value of the total investment in Affimed N.V. decreased from $4,643,000 to $3,689,000 decreasing 20.5% quarter over quarter.
Telemetry Investments, L.l.c. expanded its ownership by buying 318,350 shares an increase of 653.5% from 03/31/2017 to 06/30/2017. Telemetry Investments, L.l.c. claims 367,067 shares with a value of $752,000. The total value of its holdings increased 571.4%. Creative Planning bolstered its investment by buying 25,000 shares an increase of 35.7% in the quarter. Creative Planning currently owns 95,000 shares worth $214,000. The value of the position overall is up by 48.6%.
Equity analyst SunTrust Robinson Humphrey started covering the stock with an initial rating of “Buy”.
In the last earnings report the EPS was $-0.99 and is estimated to be $-0.84 for the current year with 43,938,000 shares outstanding. Next quarter’s EPS is estimated at $-0.22 with next year’s EPS projected to be $-0.80.
Affimed N.V., launched on May 1, 2014, is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Business’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells. The Business’s research and development pipeline consists of AFM13, AFM11, AFM21, AFM22, AFM24, TandAb and Trispecific Abs. The Company generates its pipeline of product candidates from three platform technologies based on its tetravalent antibody architecture characterized by four binding domains, creating bispecific NK-cell and T-cell TandAbs (binding to two different targets) and Trispecific Abs (binding to three different targets). Its bispecific antibodies, TandAbs, are designed to direct and establish a bridge between either Natural Killer (NK)-cells or T-cells and cancer cells. The Business’s TandAbs brings NK-cells or T-cells into proximity and triggers a signal cascade that leads to the destruction of cancer cells..